Lilly’s next diabetes play would have patients swallow engineered stem cells – BioPharma Dive
Xconomy |
Lilly's next diabetes play would have patients swallow engineered stem cells
BioPharma Dive Eli Lilly & Co. and a freshly formed Massachusetts biotech are working to create a new kind of diabetes treatment: one that would have patients downing a capsule filled with insulin-producing cells. Sigilon Therapeutics Inc., which launched in mid-2017 … Lilly Licenses Sigilon's Cell Encapsulation Tech for Diabetes Therapy Eli Lilly jumps into a $473M hunt with Sigilon for the Holy Grail in diabetes cell therapies Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the … |
